The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
International medical case reports journal January 1, 2023 Daniel A Kinderlehrer 7 citations
Lyme disease can cause severe, treatment-resistant neuropsychiatric symptoms through autoimmune-driven neuroinflammation. A man with serologically confirmed neuropsychiatric Lyme disease who could not tolerate antimicrobial or psychiatric medications experienced symptom remission after starting microdosed (sub-hallucinogenic) psilocybin. A literature review suggests psilocybin's serotonergic and anti-inflammatory properties may benefit mental illness stemming from autoimmune inflammation. Further research on microdosed psilocybin for neuropsychiatric Lyme disease and autoimmune encephalopathies is warranted.